Abstract:Cardiovascular diseases are one of the leading causes of death worldwide and cardiac fibrosis is a common pathological process for cardiac remodeling in cardiovascular diseases. Cardiac fibrosis not only accelerates the deterioration progress of diseases but also becomes a pivotal contributor for futile treatment in clinical cardiovascular trials. Although cardiac fibrosis is common and prevalent, effective medicines to provide sufficient clinical intervention for cardiac fibrosis are still unavailable. Traditional Chinese medicine (TCM) is the natural essence experienced boiling, fry, and other processing methods, including active ingredients, extracts, and herbal formulas, which have been applied to treat human diseases for a long history. Recently, research has increasingly focused on the great potential of TCM for the prevention and treatment of cardiac fibrosis. Here, we aim to clarify the identified pro-fibrotic mechanisms and intensively summarize the application of TCM in improving cardiac fibrosis by working on these mechanisms. Through comprehensively analyzing, TCM mainly regulates the following pathways during ameliorating cardiac fibrosis: attenuation of inflammation and oxidative stress, inhibition of cardiac fibroblasts activation, reduction of extracellular matrix accumulation, modulation of the renin-angiotensin-aldosterone system, modulation of autophagy, regulation of metabolic-dependent mechanisms, and targeting microRNAs. We also discussed the deficiencies and the development direction of anti-fibrotic therapies on cardiac fibrosis. The data reviewed here demonstrates that TCM shows a robust effect on alleviating cardiac fibrosis, which provides us a rich source of new drugs or drug candidates. Besides, we also hope this review may give some enlightenment for treating cardiac fibrosis in clinical practice.

CAR‐T cell therapeutic avenue for fighting cardiac fibrosis: Roadblocks and perspectives

Targeting cardiac fibrosis with Chimeric Antigen Receptor-Engineered Cells

Preclinical scenario of targeting myocardial fibrosis with chimeric antigen receptor (CAR) immunotherapy

[Treatment of cardiac fibrosis: from neurohormonal antagonists to CAR-T cells]

Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy

T cell immunotherapy for cardiac fibrosis: mRNA starts the CAR

Cardiac-derived stem cell-based therapy for heart failure: progress and clinical applications.

CAR-Macrophage Therapy Alleviates Myocardial Ischemia-Reperfusion Injury

Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies

Targeting cardiac fibrosis with engineered T cells

Harnessing stem cell and lineage reprogramming technology to treat cardiac fibrosis

CAR T cells produced in vivo to treat cardiac injury

Application and research progress of CAR-T cell therapy in autoimmune diseases

Cardiac Cell Therapy for Heart Repair: Should the Cells Be Left Out?

Traditional Chinese medicine as a therapeutic option for cardiac fibrosis: Pharmacology and mechanisms

Adverse Cardiac Effects of CAR T-Cell Therapy: Characteristics, Surveillance, Management, and Future Research Directions

Cardiac Cell Therapy: Insights into the Mechanisms of Tissue Repair

Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases

CAR T treatment beyond cancer: Hope for immunomodulatory therapy of non-cancerous diseases

The adaptive immune response to cardiac injury—the true roadblock to effective regenerative therapies?

Novel Therapies for the Treatment of Cardiac Fibrosis Following Myocardial Infarction